Immunotherapies that activate the immune system to seek and kill cancer cells have greatly improved outcomes for many patients with solid tumors. There is still, however, a subset of patients who do not see benefit from this type of therapy. Currently, there are no immune biomarkers that explain how patients with similar disease and patient characteristics can have different outcomes. In a new article published in the Journal for ImmunoTherapy of Cancer, Moffitt Cancer Center researchers demonstrate how mathematical modeling can be used to analyze the impact of different cancer treatments on tumor and immune cell dynamics and help predict outcomes to therapy and personalize cancer treatment.
